School of Medicine
Showing 1-9 of 9 Results
-
Yunkyeong Lee
Postdoctoral Scholar, Endocrinology and Metabolism
BioYun is a postdoctoral research scholar in Dr. Anna Gloyn lab (Translational Genomics of Diabetes Lab). Since she joined the lab in August 2022, she has been involved in projects investigating type 2 diabetes (T2D) susceptible genes and their molecular mechanisms for pancreatic beta cell dysfunction under the mentorship of Dr. Gloyn. In particular, she is interested in how T2D effector transcripts alter the autophagy/mitophagy pathways in human pancreatic beta cells and how this may lead to beta cell failure, mitochondrial dysfunction and T2D pathology. She has been also using CRISPR knock-in genome editing in human induced pluripotent stem cell and its derivatives to reveal loss of function variant that causes transient neonatal diabetes.
During her PhD, she focused on the roles of an epigenetic regulator and its molecular machineries in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Besides, she studied the correlation between endoplasmic reticulum (ER) stress-mediated unfolded protein response (UPR) signalling and autophagy, and further their effects on various cells using some plant extracts. Her research goal is to expand our knowledge about the cellular and molecular mechanisms of T2D and explore therapeutic targets and/or strategies. -
Seth Andrew Sharp
Postdoctoral Scholar, Endocrinology and Metabolism
BioSeth is a Postdoctoral Fellow in the Translational Genomics of Diabetes lab located at Stanford Research Park under the supervision of Professor Anna Gloyn. Seth completed a B.E. in Applied Mathematics before studying a PhD at the University of Exeter with Dr Richard Oram where he researched the use of genetics to predict common autoimmune disorders. Seth studied at the Alan Turing Institute in London where he used machine learning and artificial intelligence methods to predict autoimmunity and has worked collaboratively to improve screening of Type 1 diabetes from birth. Seth's postdoctoral studies focus on using genetic, transcriptomic and epigenetic data to understand the mechanisms by which both Type 1 and Type 2 diabetes occur in the human pancreas. He is also interested in ways to quantify genetic risk such as polygenic risk scores and their application in both research and clinic.
-
Yanxian Zhang
Postdoctoral Scholar, Endocrinology and Metabolism
BioThrough my academic training and research experience, I have cultivated a strong foundation in engineering and molecular biology. My work involves integrating diverse concepts from disciplines such as chemical engineering, protein engineering, supramolecular chemistry, and biophysics to address complex biomedical challenges. As a graduate student with Dr. Jie Zheng, my research focused on both natural and synthetic macromolecules. My research involved utilizing polymer chemistry to design biocompatible multifunctional hydrogels, as well as investigating the thermodynamics of amyloid proteins associated with neurodegenerative diseases. Leveraging my expertise in thermodynamics and supramolecular chemistry, I contributed to the study of understanding protein misfolding and aggregation. I identified sequence-independent inhibitors to prevent protein misfolding and developed a rational strategy for inhibitor design, enabling cross-interaction activity and the fluorescent detection of amyloids. Driven by a strong interest in translational research, I pursued postdoctoral training here at Stanford School of Medicine. In Dr. Danny Hung-Chieh Chou's lab at Stanford University, I received comprehensive training in peptide engineering and molecular biology. I am dedicated to addressing formulation challenges for insulin with stable ultra-concentrated and ultra-fast properties, aimed at miniaturizing insulin pumps and advancing the next-generation of insulin automatic delivery systems. This work is supported by the JDRF postdoctoral fellowship. Furthermore, I am working on therapeutics development and have successfully developed an insulin derivative that acts as a full insulin receptor antagonist. This development holds promise as a candidate for treating the rare disease of hyperinsulinism. Throughout my postdoctoral training, I have gained proficiency in grant writing, public speaking, and mentoring students. These experiences have significantly strengthened my skills as an independent investigator. Looking forward, my research goal is to develop innovative strategies that support the functionality and delivery of biological therapies.
